Company intelligence / Profile preview

Lohxa

North Oxford, Massachusetts, United States

Ownership: Private
Development stage: Commercial

Overview

Lohxa provides FDA/DEA-approved contract manufacturing, private labeling, and repackaging services with a focus on oral unit dose packaging. The company serves OTC, prescription, dietary supplement, and cosmetic markets using advanced technology and strict quality control. No proprietary clinical results as it does not develop its own drugs.

Therapeutic areas: OtherDermatologyMetabolic Disorders
Modalities: Small molecule (OTC and Rx drugs)Dietary supplement (as a product class)Cosmetic ingredient/formulation (as a product class)Liquid formulation (dosage form)
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

mupirocin

Commercial

Indications: Skin infections, MRSA infections

Beyond the preview

Go deeper on Lohxa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lohxa.

Explore the full profile